Abhijeet Ghatol
Pulmonary Disease · Flint, MINPI 1598929978
Payments from drug & device makers
Across 56 payments — averaging $95.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$156
- AstraZeneca$152
- Baxter Healthcare$149
- Amgen$110
- Medtronic$83
- plus $375 from 15 others
What the payments were for
- Travel & lodging$1,81234%
- Food & beverage$1,04319%
- Education$2,50047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $4,329 |
| GSK | 8 | $156 |
| AstraZeneca | 8 | $152 |
| Baxter Healthcare | 5 | $149 |
| Amgen | 5 | $110 |
| Medtronic | 1 | $83 |
| Merck | 2 | $46 |
| Boehringer Ingelheim | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Pulmonx Corporation | 1 | $37 |
| Insmed, Inc. | 1 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Resmed Corp | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Inogen, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,243
How this compares
$5,356 in reported general payments places this provider in the 65th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 297 | $287,138 |
| OfevNintedanib Esylate | 12 | $144,106 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 127 | $77,165 |
| Dupixent PenDupilumab | 14 | $50,157 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $34,796 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $24,286 |
| Spiriva RespimatTiotropium Bromide | 34 | $18,092 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $15,550 |
| Spiriva HandihalerTiotropium Bromide | 20 | $12,395 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $12,207 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $12,161 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $11,536 |
| Tiotropium Bromide | 18 | $10,974 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 273 | $9,636 |
| Ventolin HfaAlbuterol Sulfate | 103 | $5,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $156 | $388,671471 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $45 | $186,48378 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $152 | $50,34676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Flint
- John YoussefFlint$92K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.